[Hypotensive effect of carteolol in patients with essential hypertension].
The ability of 5-(3-tert-butylamino-2-hydroxy-propoxy)-3, 4-dihydro-2(1H)-quinolinone hydrochloride (carteolol hydrochloride, Endak, Endak mite) to lower the blood pressure was tested in an open clinical study on 66 patients with I-III degree essential hypertension. The results for 49 of the 66 patients were interpretable after 4 weeks, and for 39 of them after 12 weeks. Even with a single dose of 5 mg/day 33 of the patients had normalized blood pressures after 4 weeks (systolic less than 160, diastolic less than 95 mmHg); in a further 6 patients 10 mg led to normal blood pressure. For 10 patients, 4 weeks on 10 mg did not lead to an adequate response. After 12 weeks, of the 39 cases that could be checked, 19 were normalized on 5 mg, 2 on 10 mg and another 4 on 15 mg. Even 15 mg was insufficient to reduce the blood pressure of 14 of the patients adequately. Carteolol, at doses of 5-15 mg/day, caused a therapeutically acceptable lowering of the blood pressure in 60-80% of cases of essential hypertension of all 3 degrees of severity. Only 5 of the patients suffered from side-effects, none of which caused the treatment to be abandoned. A bradycardia was never observed during up to 12 weeks of continuous treatment. Tachycardias reverted to sinus rhythms of normal frequency. Blood pressure measurement by the patients themselves proved successful.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002354:Carteolol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines; D002354:Carteolol
Die hypotensive Wirkung von Carteolol bei Patienten mit essentieller Hypertonie.